Results 201 to 210 of about 294,750 (308)

Selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor use and sexual dysfunction: a pharmacovigilance analysis. [PDF]

Sex Med
Shen M, He L, Chen P, Zhang L, Zeng D, Li Y, Li H.   +6 more
europepmc   +1 more source

Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Reduced cardiac uptake on 123Iodine‐metaiodobenzylguanidine (MIBG) scintigraphy is a valuable tool for differentiating neurodegenerative parkinsonism but interpretation can be difficult due to comorbidities and drug‐tracer interactions.
Frank Jagusch, Elena Redl, Christoph Theyer, Atbin Djamshidian, Alessandra Fanciulli, Werner Poewe, Philipp Mahlknecht, Beatrice Heim, Klaus Seppi, Florian Krismer   +9 more
wiley   +1 more source

Research progress on the oligosaccharide components and pharmacological activities of <i>Morinda officinalis</i>. [PDF]

Front Chem
Lei Y, Wang Z, Dan Y, Xie Y, Wang Y, Wang X, Zhang L.   +6 more
europepmc   +1 more source

High Prevalence and Clinical Impact of Fibromyalgia in Functional Motor Disorder

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fibromyalgia is characterized by widespread pain, fatigue, sleep and cognitive symptoms. It overlaps clinically with functional motor disorder (FMD), yet its prevalence and impact in FMD remain uncertain. Objective To determine the prevalence of fibromyalgia in FMD using the current criteria and evaluate its effects on motor ...
Tereza Serranová, Lucia Nováková, Martin Jirásek, Barbora Křupková, Evžen Růžička, Michele Tinazzi, Tomáš Sieger   +6 more
wiley   +1 more source

Perspective: Depression in Persons with Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Depression is a prevalent and disabling syndrome characterized by sustained sadness and/or anhedonia, as well as cognitive and physical symptoms. In Parkinson's disease (PD), depression is both common and clinically challenging due to overlapping symptoms and complex etiologic interactions. Major depressive disorder occurs in approximately 17%
Albert F.G. Leentjens, Gregory M. Pontone   +1 more
wiley   +1 more source

<i>Rhodiola rosea</i>, <i>Ginkgo biloba</i>, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders. [PDF]

Front Nutr
Li X, Li X, Li Y, Liu Z, Cai Y, Yao Q, Zhao S, Yu Q.   +7 more
europepmc   +1 more source

Temporal Interference Stimulation Modulates Resting State Functional Connectivity of Motor Circuit in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Transcranial temporal interference stimulation (TIs) targeting the subthalamic nucleus (STN) is a novel noninvasive neuromodulation approach with potential to improve motor symptoms in Parkinson's disease (PD). However, its underlying neuroimaging mechanisms remain unclear.
Yongxin Xu, Chenhao Yang, Yichao Du, Xiaonan Shen, Tingting Li, Yufeng Zhang, Zijun Lu, Jie Zhuang, Nan Chen, Yulian Zhu, Chencheng Zhang, Jiaojiao Lü, Lingyan Huang, Lu Li, Jianqiang Lü, Zhenyu Qian, Zhen Wang, Jian Zhang, Junhong Zhou, Yu Liu   +19 more
wiley   +1 more source

Impact of Antihypertensive, Antihyperlipidemic, and Mixed Antidepressant Medications on Dental Implant Success: A Retrospective Cohort Study. [PDF]

Cureus
Chidiac A, Kachouh C, M Sadaka R, Bassil J.   +3 more
europepmc   +1 more source